| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, Japan;
Department of Developmental Immunology, Osaka University Graduate School of Frontier Biosciences, Yamadaoka, Suita, Osaka, Japan; and
Department of Developmental Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
IL-2 is a potent immunostimulant and has been tested for clinical use, including in immunotherapy for cancers and HIV infection. Here we show that a widely used neutralizing anti-murine IL-2 mAb (S4B6) exhibits unexpected activities that enhance the treatment effects of IL-2 in vivo. Coinjection of the anti-IL-2 mAb with a plasmid carrying murine IL-2 cDNA significantly increased the serum IL-2 levels and induced a substantial increase in the division of CD8+ T and NK1.1high cells in vivo. Injection of the mAb premixed with recombinant murine IL-2 showed the same enhanced effect. A 5-day treatment with the anti-IL-2 mAb alone gradually increased the CD44highCD8+ population, and the increased population was maintained for >300 days, suggesting that the mAb can gradually maintain and potentially enhance the bioactivity of endogenous IL-2 for extended periods. Furthermore, combined treatment with the anti-IL-2 mAb plus the IL-2 plasmid markedly enhanced Ag-specific CTL activity in vivo and partially protected mice from tumor metastasis to the lungs, compared with the anti-IL-2 mAb or IL-2 plasmid alone. These results demonstrated IL-2-enhancing effects of the anti-IL-2 mAb in vivo and suggest that combining a neutralizing anti-IL-2 Ab with IL-2 gene delivery might be used effectively to enhance IL-2 functions in clinical applications.
This article has been cited by other articles:
|
|
 |
|
  J. Tomala, H. Chmelova, T. Mrkvan, B. Rihova, and M. Kovar In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy J. Immunol., October 15, 2009; 183(8): 4904 - 4912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Molloy, W. Zhang, and E. J. Usherwood Cutting Edge: IL-2 Immune Complexes As a Therapy for Persistent Virus Infection J. Immunol., April 15, 2009; 182(8): 4512 - 4515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Wilson, J. T. Pesce, T. R. Ramalingam, R. W. Thompson, A. Cheever, and T. A. Wynn Suppression of Murine Allergic Airway Disease by IL-2:Anti-IL-2 Monoclonal Antibody-Induced Regulatory T Cells J. Immunol., November 15, 2008; 181(10): 6942 - 6954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Rubinstein, N. A. Lind, J. F. Purton, P. Filippou, J. A. Best, P. A. McGhee, C. D. Surh, and A. W. Goldrath IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response Blood, November 1, 2008; 112(9): 3704 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Verdeil, K. Marquardt, C. D. Surh, and L. A. Sherman Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy PNAS, October 28, 2008; 105(43): 16683 - 16688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kamimura and M. J. Bevan Endoplasmic Reticulum Stress Regulator XBP-1 Contributes to Effector CD8+ T Cell Differentiation during Acute Infection J. Immunol., October 15, 2008; 181(8): 5433 - 5441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-H. Jin, T. Hirano, and M. Murakami Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation Int. Immunol., June 1, 2008; 20(6): 783 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Boyman, C. Ramsey, D. M. Kim, J. Sprent, and C. D. Surh IL-7/Anti-IL-7 mAb Complexes Restore T Cell Development and Induce Homeostatic T Cell Expansion without Lymphopenia J. Immunol., June 1, 2008; 180(11): 7265 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Epardaud, K. G. Elpek, M. P. Rubinstein, A.-r. Yonekura, A. Bellemare-Pelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley Interleukin-15/Interleukin-15R{alpha} Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells Cancer Res., April 15, 2008; 68(8): 2972 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mostbock, M. E. C. Lutsiak, D. E. Milenic, K. Baidoo, J. Schlom, and H. Sabzevari IL-2/Anti-IL-2 Antibody Complex Enhances Vaccine-Mediated Antigen-Specific CD8+ T Cell Responses and Increases the Ratio of Effector/Memory CD8+ T Cells to Regulatory T Cells J. Immunol., April 1, 2008; 180(7): 5118 - 5129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Prlic, D. Kamimura, and M. J. Bevan Rapid generation of a functional NK-cell compartment Blood, September 15, 2007; 110(6): 2024 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kamimura and M. J. Bevan Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo J. Exp. Med., August 6, 2007; 204(8): 1803 - 1812. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
